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Purpose: To test the hypothesis that cardiac comorbidity before the start of radiotherapy (RT) is associ-
ated with an increased risk of radiation-induced lung toxicity (RILT) in lung cancer patients.
Material and methods: A retrospective analysis was performed of a prospective cohort of 259 patients
with locoregional lung cancer treated with deﬁnitive radio(chemo)therapy between 2007 and 2011 (Clin-
icalTrials.gov Identiﬁers: NCT00572325 and NCT00573040). We deﬁned RILT as dyspnea CTCv.3.0 grade
P2 within 6 months after RT, and cardiac comorbidity as a recorded treatment of a cardiac pathology at a
cardiology department. Univariate and multivariate analyses, as well as external validation, were per-
formed. The model-performance measure was the area under the receiver operating characteristic curve
(AUC).
Results: Prior to RT, 75/259 (28.9%) patients had cardiac comorbidity, 44% of whom (33/75) developed
RILT. The odds ratio of developing RILT for patients with cardiac comorbidity was 2.58 (p < 0.01). The
cross-validated AUC of a model with cardiac comorbidity, tumor location, forced expiratory volume in
1 s, sequential chemotherapy and pretreatment dyspnea score was 0.72 (p < 0.001) on the training set,
and 0.67 (p < 0.001) on the validation set.
Conclusion: Cardiac comorbidity is an important risk factor for developing RILT after deﬁnite
radio(chemo)therapy of lung cancer patients.
 2013 The Authors. Published by Elsevier Ireland Ltd. RadiotherapyOpen access under CC BY-NC-ND license.00–106Radiation-induced lung toxicity (RILT) is an important dose-
limiting complication of radical thoracic radiotherapy (RT). While
high radiation doses are expected to provide better locoregional
control, associated toxicity, such as RILT, may have a major impact
on the quality of life and can even be lethal. About 10%-20% of all
lung cancer patients treated with radio(chemo)therapy, R(CH)T,
develop RILT within 6 months after start of treatment, with clinical
symptoms of dyspnea, cough, and sometimes fever [1]. Notably,
the degree of RILT varies greatly among patients treated with sim-
ilar dose levels to the healthy lung. Identiﬁcation of patients’ sus-
ceptibility to RILT prior to RT based on baseline characteristicsmay permit (1) dose escalation for low-risk patients, potentially
leading to better survival rates at reduced/similar levels of treat-
ment-related side effects [2] and (2) dose reduction/redistribution
for high-risk patients to avoid side effects.
Traditional risk factors for RILT include mean lung dose (MLD),
V20 Gy (volume of lung receiving at least 20 Gy), age, smoking sta-
tus, gender, World Health Organization (WHO) performance status,
chemotherapy, and the location of the primary lung tumor ([3–14],
among others). Unfortunately, prognostic models based on these
factors have not provided consistent performance across different
studies. Blood biomarkers have likewise shown controversial re-
sults, [15–17]. Recently, preclinical [18] and clinical [19] studies
have demonstrated a short-term effect of irradiation of a healthy
heart on pulmonary dysfunction. Left-sided heart failure is known
to lead to dyspnea due to an elevated end-diastolic pressure of the
left ventricle, which perpetrates to the pulmonary capillaries and
leads to pulmonary edema, [20,21]. Moreover, cardiac comorbidity
at the start of treatment among 3864 lung cancer patients with a
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comitant disease, with incidence twice as high (23%) as in the gen-
eral population, [22]. We therefore hypothesized that patients with
recorded historical treatment of cardiac pathologies are at greater
risk of developing RILT after R(CH)T.Material and methods
Patient population and inclusion criteria
Between 2008 and 2011 a total of 399 lung cancer patients, all
treated in two hospitals with cardiology departments, were re-
ferred to our institute for radiation treatment and used in our ret-
rospective study. Of these, 259 patients retrospectively met the
inclusion criteria of the study, namely: stage I-IIIB, (chemo)radio-
therapy with curative intent, radiation fraction dose 63 Gy. Stereo-
tactic body irradiation treatments were excluded. All patients
underwent a FDG-PET/CT scan for treatment planning purposes,
on which the heart and lungs (manual contouring in either medi-
astinal or lung WW/WL-setting as appropriate) were delineated.
The treatment planning system used was XiO (4.3.4, CMS, St. Louis,
USA) using the superposition dose calculation algorithm. Patients
were treated with concurrent or sequential chemoradiotherapy,
(postoperative) radiotherapy with subsequent adjuvant chemo-
therapy, or with radiation alone. Sequential chemotherapy con-
sisted of carboplatin on day 1 and gemcitabine on day 1 and 8.
The majority of the patients received 3 cycles (range 1–6). Concur-
rent chemo radiation consisted of cisplatin on day 1 and 8 and eto-
poside on day 1–3 of a three-weekly cycle. In total three cycles
were given. The patients were examined weekly during RT and
every three months thereafter by either the radiation oncologist
or the chest physician. Patient characteristics for the training
(n = 259) as well as the validation dataset (n = 107 from Ghent Uni-
versity Hospital and n = 44 from Radboud University Nijmegen
Medical Centre) are given in Table 1.Toxicity scoring
RILT was scored using the Common Terminology Criteria for Ad-
verse Events version 3.0 (CTCAEv3.0) before, weekly during and
every 3 months after RT by either a chest physician or a radiation
oncologist. A value of dyspnea P2 within 6 months after RT was
considered as acute manifestation of RILT and used as primary
endpoint in the analysis. In the CTCAE3.0 system, grade 0 is no
dyspnea; grade 1 is dyspnea on exertion, but can walk 1 ﬂight of
stairs without stopping; grade 2 is dyspnea on exertion but unable
to walk 1 ﬂight of stairs or 100 meters without stopping; grade 3 is
dyspnea with ADLs (Activities of Daily Living. Basic ADLs include
eating, dressing, getting into or out of a bed or chair, taking a bath
or shower, and using the toilet.); grade 4 is dyspnea at rest, intuba-
tion/ventilator indicated; and grade 5 is death.Cardiac comorbidity scoring
Cardiac comorbidity was deﬁned as a recorded historical treat-
ment of any cardiac disorder at a cardiology department before the
start of RT, irrespective of its severity. Cardiac comorbidity for all
patients was scored by a cardiologist from the academic hospital
azM Maastricht using the cardiac speciﬁc anamnesis from the car-
diology departments. Patient dyspnea scores were not provided to
the cardiologist.Statistical analysis
We tested four statistical hypotheses:(1) the independence of cardiac comorbidity and post-treatment
dyspnea P2, our main clinical hypothesis being that we
reject such independence;
(2) the independence of cardiac comorbidity and post-treatment
dyspnea P2, given pretreatment dyspnea <2, to determine
whether cardiac comorbidity might be a risk factor only
for patients who already have high dyspnea levels at the
start of RT;
(3) the independence of cardiac comorbidity and post-treatment
dyspneaP3, to determine the robustness of the ﬁrst hypoth-
esis, in case it is not rejected;
(4) the independence of cardiac comorbidity and pretreatment
dyspnea, In case cardiac comorbidity is a risk factor for
post-RT dyspnea, it may be also be more likely that presence
of cardiac comorbidity is associated with higher levels of
pretreatment dyspnea.
The univariate and multivariate logistic regression analyses
were performed in SPSS version 19 (IBM Corp., Armonk, NY) and
MATLAB (MathWorks Inc., Natick, MA). The following variables
were considered as inputs for the prediction models: MLD, existing
cardiac comorbidity at the start of radiotherapy, smoking status,
type of chemotherapy, age, gender, forced expiratory volume in
1 s adjusted for gender and age (FEV1, in%), lung surgery performed
in the past before RT, WHO performance status (WHOps), tumor
location, lung volume, prescribed tumor dose expressed as equiva-
lent radiation dose in 2 Gy fractions corrected for overall treatment
time (EQD2,t) [23] using a/b = 10 Gy and accelerated repopulation
kick-off time of 28 days, overall treatment time, and the level of
dyspnea at the start of RT. In addition, mean heart dose (MHD)
was available for the patients in the training set, which is available
online at www.cancerdata.org/?q=10.1016/j.radonc.2013.08.035.
The variables for the multivariate model were selected via a wrap-
per feature selection procedure, [24], on the training set using a 10-
fold cross validation with AUC set as a performance criterion. This
feature selection method was performed in WEKA (Waikato Envi-
ronment for Knowledge Analysis, [25]). An alpha value of 0.05 was
used as a threshold for statistical signiﬁcance. The p-values for
nominal variables were computed using a chi-square test. Model
performance was evaluated using the area under the receiver oper-
ator characteristic curve (AUC) estimated from a 10-fold cross-val-
idation procedure to avoid the problem of overﬁtting; p-values for
the difference in AUC vis-à-vis AUC = 0.5 (randommodel) were cal-
culated using 1000 bootstrap samples. Univariate and multivariate
analyses were performed on the training set and validated on the
validation set.Results
Among the 259 patients from the training dataset, 76 (29.3%)
had a maximum dyspnea score P2 after RT. Out of them, 33
(43.4%) had a cardiac comorbidity at the start of RT. As the total
number of patients with cardiac comorbidity was 75, this means
that 44% (33/75) of the cardiac-comorbidity patients developed
RILT. Conversely, 23.4% (43/184) of the patients without cardiac
comorbidity experienced RILT.Cardiac comorbidity and dyspnea P2
The odds ratio of post-RT dyspnea P2 for patients with versus
without cardiac comorbidity was 2.6 (p = 0.0009, 95% conﬁdence
interval (CI): 1.5–4.5; Table 3 and Supplement Figure 1). These
ﬁndings were conﬁrmed on the combined validation set from
two university hospitals (n = 151), with corresponding odds ratio
of 2.3 (p = 0.039, 95% CI: 1.03–4.9). The relative risk of RILT in
Table 1
Patient characteristics.
Variable No. of patients (%)
Training set (n = 259) Ghent set (n = 107) Nijmegen set (n = 44)
Gender
Male 163(62.9) 94(87.8) 36(81.8)
Female 96(37.1) 13(12.2) 8(18.2)
Smoking status
Current smoker 77(29.7) 34(31.8) 11(25.0)
Histopathology
NSCLC 198(76.5) 88(93.5) 43(97.7)
SCLC 49(18.9) 11(10.3) 0(0)
NSCLC + SCLC 0(0) 1(0.9) 0(0)
cT-stage
0 or 1 48(18.5) 9(8.4) 10(22.7)
2 75(29.0) 33(30.8) 14(31.8)
3 40(15.4) 32(29.9) 11(25.0)
4 95(36.7) 20(18.7) 9(20.5)
cN-stage
0 67(25.9) 17(15.9) 2(4.5)
1 19(7.3) 9(8.4) 2(4.5)
2 112(43.2) 47(44.0) 35(79.5)
3 60(23.2) 23(21.5) 5(11.4)
WHO-ps
0 63(24.3) 52(48.6) 25(56.8)
1 153(59.1) 48(44.9) 14(31.8)
P2 43(16.6) 6(5.61) 5(11.4)
Chemotherapy
Yes 197(76.1) 98(91.6) 41(93.2)
Concurrent 148(57.1) 39(36.4) 22(50.0)
Sequential before RT 39(15.1) 56(52.3) 19(43.2)
Adjuvant (after surgery) 9(0.03) 0(0) 0(0)
Palliative 1(0.01) 0(0) 0(0)
Concurrent + adjuvant 0(0) 3(0.03) 0(0)
No 44(17.0) 9(8.41) 3(6.8)
Cardiac comorbidity
No 184(71.0) 86(80.4) 13(29.5)
Yes 75(29.0) 21(19.6) 31(70.5)
Baseline dyspnea score
0 78(30.1) 46(43.0) 15(34.1)
1 140(54.1) 25(23.4) 25(56.8)
2 22(8.5) 19(17.8) 4(9.1)
3 15(5.8) 2(1.9) 0(0)
4 1(0.4) 0(0) 0(0)
Maximal dyspnea score
0 49 (18.9) 19 (17.8) 4 (9.1)
1 134 (51.7) 47 (44.0) 28 (63.6)
2 40 (15.4) 34 (31.8) 8 (18.2)
3 32 (12.4) 5 (4.7) 4 (9.1)
4 4 (1.5) 2 (1.9) 0(0)
Tumor location
Lower/middle lobe 76 (29.3) 33 (30.8) 15 (35.7)
Upper lobe 83 (32.1) 67 (62.6) 27 (64.3)
Lung surgery before RT
Yes 23 (8.9) 15 (14.0) 0(0)
No 236 (91.1) 92 (86.0) 44 (100.0)
Mean (SD)
OTT 30.21 (7.45) 47.8 (11.1) 43.37 (3.49)
Age, years 67.5 (10.1) 64.0 (8.8) 65.94 (7.69)
Prescribed tumor dose, Gy 62.4 (9.92) 64.5 (8.58) 64.66 (4.13)
EQD2,t 58.83 (9.51) 51.97 (5.94) 54.60 (2.35)
Dose per fraction 1.836 (0.342) 1.981 (0.172) 2.02 (0.15)
MLD, Gy 15.65(4.44) 13.1 (4.31) 16.23 (3.12)
V20 Gy 25.45 (9.87) 19.35 (7.71) Not available
FEV1 (in%) 75.96 (21.86) 75.7 (20.56) 77(17.44)
Abbreviations: No./n, number; SD, standard deviation; cT-stage, clinical tumor stage; cN-stage, clinical lymph node stage; NSCLC, non-small-cell lung cancer; SCLC, small-
cell-lung cancer; WHO-ps, World Health Organization performance status; OTT, overall treatment time (in days); EQD2,t, equivalent radiation dose at 2 Gy per fraction,
adjusted for time; MLD, mean lung dose; V20 Gy, volume of the healthy lung receiving a dose of at least 20 Gy; FEV1 (in%), forced expiratory volume in 1 s (in%) adjusted for
age and gender. Dyspnea is measured according to the Common Toxicity Criteria for Adverse Effects, version 3.0; maximal dyspnea is measured within 6 months after the
start of R(CH)T.
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comorbidity (17/34).Cardiac comorbidity and maximal dyspnea P2, given baseline
dyspnea <2
The odds ratio of post-RT dyspnea in this case turned out to be
similar to the one found without the restriction on baseline dysp-
nea grade: 2.6 (p = 0.005, 95% CI: 1.3–5.1; Table 3).Cardiac comorbidity and maximal dyspnea P3
With this test we checked the robustness of the main ﬁnding,
which is conﬁrmed: the odds ratio is 2.5 (p = 0.009, 95% CI: 1.2–
5.2, see Table 3). Even though the corresponding odds ratio on
the validation set was 2.1, the chi-square test was not performed
due to the insufﬁcient (less than 5) number of patients with both
cardiac comorbidity and maximal dyspnea P3.Cardiac comorbidity and baseline dyspnea
Cardiac comorbidity is an independent cause of dyspnea, so
therefore it is likely that the presence of cardiac comorbidity is
associated with higher levels of baseline dyspnea. In this study,Table 3
Contingency tables, odds ratios (with 95% CI) and p-values for the hypotheses that (1) maxim
dyspnea is 61, or (3) the outcome is maximal dyspneaP3. Results are shown for both the t
contains cells with counts <5.
Dataset Training set Validation set Training set
Baseline dyspnea =
max
dyspn < 2
max
dyspnP 2
max
dyspn < 2
max
dyspnP 2
max
dyspn < 2
max
dyspnP
With CC 42 33 17 17 38 20
No CC 141 43 81 36 133 27
Odds ratio
(95% CI)
2.58 (1.46–4.55) 2.25 (1.03–4.90) 2.59 (1.31–5.12)
p-value 0.0009 0.039 0.005
n 259 151 218
CC, cardiac comorbidity; CI, conﬁdence interval; n, number; max dyspn, maximal dyspn
Table 2
Results for univariate and multivariate logistic regressions for all variables and selected v
within 6 months from the start of RT.
Variable Univariate
Coefﬁcient S.E. p-value*
Intercept
Smoking status 0.029 0.302 0.924
Sequential chemotherapy 0.671 0.363 0.064
Concurrent chemotherapy 0.789 0.290 0.007
Gender 0.094 0.284 0.741
Cardiac comorbidity 0.969 0.289 0.001
Surgery 0.057 0.475 0.904
Tumor location 0.185 0.369 0.616
WHO-ps 0.055 0.176 0.755
Age 0.025 0.014 0.078
FEV1 (in %) 0.016 0.007 0.018
MLD 0.005 0.031 0.872
EQD2,t 0.022 0.014 0.126
Overall treatment time 0.002 0.018 0.914
Baseline dyspnea score 1.015 0.196 <0.000
Model performance (AUC)
Training set, 10-fold cross validation
Validation set
S.E. standard error, n.a. not applicable; abbreviations, see Table 1.
* p-values for coefﬁcients were calculated by multivariate logistic regression; p-values f
the AUC was different from 0.5 (a ﬂip-of-a-coin model).we rejected the independence of these two factors on the training
set: the odds ratio of observing baseline dyspnea P2 for patients
with cardiac comorbidity was 2.2 (p = 0.02, 95% CI: 1.1–4.5; Sup-
plement Table 1).MHD, cardiac comorbidity and dyspnea P2
We performed a Kruskal–Wallis test for signiﬁcant difference
between median MHDs across the following four groups in the
training set: patients with/without cardiac comorbidity and with/
without maximal dyspnea P2. The p-value of the test was 0.71,
suggestive of no signiﬁcant difference across the four groups (Sup-
plement Figure 2).Cardiac comorbidity and maximal dyspneaP2, given that the patient
received chemotherapy
Considering the subgroup of patients who received chemother-
apy: the odds ratio of post-RT dyspneaP2 for patients with versus
without cardiac comorbidity was 2.6 (p = 0.005, 95% CI: 1.3–5.1;
Supplement Table 2). These ﬁndings were conﬁrmed on the com-
bined validation set (n = 139), with corresponding odds ratio of
2.3 (p = 0.05, 95% CI: 0.97–5.3).al dyspneaP2 and cardiac comorbidity are independent, even when (2) the baseline
raining set and the validation set. A p-value is not computed when a contingency table
Validation set Training set Validation set
0 or 1
2
max
dyspn < 2
max
dyspnP 2
max
dyspn < 3
max
dyspnP 3
max
dyspn < 3
max
dyspnP 3
15 11 58 17 30 4
60 25 165 19 110 7
1.76 (0.71–4.36) 2.55 (1.24 – 5.23) 2.10
0.219 0.009 n.a.
111 259 151
ea (within 6 months from the start of RT).
ariables based on the wrapper approach. Dependent variables: maximal dyspnea P2
Multivariate: all variables Multivariate: selected variables
Coefﬁcient S.E. p-value* Coefﬁcient S.E. p-value*
0.803 1.614 0.619 1.512 0.664 0.023
0.185 0.306 0.546 n.a n.a n.a
0.601 0.449 0.180 0.610 0.394 0.122
0.016 0.416 0.969 n.a n.a n.a
0.005 0.313 0.988 n.a n.a n.a
0.817 0.307 0.008 0.826 0.312 0.008
0.196 0.533 0.713 n.a n.a n.a
0.421 0.314 0.180 0.290 0.347 0.404
0.077 0.191 0.684 n.a n.a n.a
0.016 0.016 0.340 n.a n.a n.a
0.012 0.007 0.077 0.007 0.007 0.330
0.02 0.034 0.565 n.a n.a n.a
0.007 0.018 0.713 n.a n.a n.a
0.017 0.018 0.345 n.a n.a n.a
1.106 0.203 <0.000 0.990 0.210 <0.000
AUC
0.723 <0.01
0.674 <0.01
or AUCs were calculated by 1000 bootstraps and a 1-sided Student’s t-test testing if
Fig. 1. A nomogram for the multivariate model (with variable selection) for the prediction of maximal dyspnea P2 within six months after RT (probability of max dyspnea
P2).
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We tested for an association between cardiac comorbidity and
smoking status, which we refuted on both the training and valida-
tion sets (Supplement Table 1).
Univariate and multivariate analyses: cardiac comorbidity,
baseline dyspnea score, and FEV1 were found to be statistically sig-
niﬁcant factors in univariate logistic regression analysis (Table 2).
Regarding chemotherapy, sequential chemotherapy was margin-
ally signiﬁcant and concurrent was signiﬁcant (having opposite
sign of the sequential). The wrapper-based feature selection on
the training set resulted in the following subset of variables, whichFig. 2. ROC curves for the multivariable model (with selected variables) for
predicting maximal dyspnea P2 within 6 months after the start of RT on the
training set (solid line, cross-validated AUC = 0.72) and the validation set (dashed
line, AUC = 0.67), as well as the ROC curve for the model including only mean lung
dose as a predictor (dotted line, AUC = 0.50).we used in our multivariate model: cardiac comorbidity, tumor
location, FEV1, lung volume, and value of pretreatment dyspnea.
The AUC’s for the multivariate model were 0.72 (p < 0.001) on
the training set, and 0.67 (p < 0.001) on the validation set. Cardiac
comorbidity, lung volume and baseline dyspnea score came out as
having the lowest p-values in the model. The AUCs of the ‘‘golden
standard’’ model having only MLD as input were 0.49 and 0.37 on
the training and the validation sets, respectively. A nomogram and
the ROC curves for the multivariate model on the training set
(computed using 10-fold cross-validation) and test sets are shown
in Fig. 1 and Fig. 2, respectively. Fig. 2 depicts also the ROC curve
for the MLD-only model. The multivariate model will be available
on www.predictcancer.org. Supplementary Figure 3 further dem-
onstrates the added value of the model at two speciﬁc points on
the ROC curve of the training-set model.Discussion
In this study we tested the hypothesis that pretreatment car-
diac comorbidity is associated with the development of RILT after
high-dose R(CH)T for lung cancer. Traditionally, the effects of radi-
ation on both organs have not been considered in tandem, most
probably due to the short-term (up to 6–9 months) pulmonary tox-
icity effect and the longer term (5–15 years) cardiac toxicity effect.
Short term cardiac toxicity has been considered in the context of
high-dose chemotherapy, [26–29], mainly for breast cancer pa-
tients. Recently, preclinical [18] and clinical [19] studies discussed
the short-term effect of irradiation of a healthy heart on pulmonary
dysfunction. They demonstrated that the heart and lungs interact
in their reaction to radiation in that excessive heart irradiation
leads to pulmonary disorders. This is somewhat surprising, given
that the heart has long been considered as the prototype (radia-
tion) dose-resistant organ, based on the long (more than 5 years)
rather than short-term increased risk of cardiac events, [30,31].
The short-term pulmonary toxicity from radiation may, however,
heavily depend on both the prior condition of the lungs and the
heart. Regarding the dose delivered to the heart, we tested whether
MHD might be a confounding factor and therefore patients with
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P2. The respective Kruskal–Wallis test for independence between
four groups of patients – with/without cardiac comorbidity and
with/without maximal dyspnea P2 – had a rather high p-value,
suggestive of no signiﬁcant difference between median MHDs
across the four groups.
The model describing the association of cardiac comorbidity
and RILT was built on one dataset and externally validated on
151 patients. A major ﬁnding of our study is that cardiac comorbid-
ity accounts for approximately 45% of all cases with dyspnea P2
after RT, even when adjusting for patients with dyspnea grade 0
and 1 at the start of treatment (Table 3). We conﬁrmed the robust-
ness of the results by considering the endpoint of maximal dyspnea
P3 and also by imposing the condition that only patients with pre-
treatment dyspnea <2 are included. The biological mechanism
underpinning the short-term interplay between existing cardiac
disorders and the effect of radiation on lung toxicity is not clear
cut and should be elucidated in the future. Furthermore, more de-
tailed subgroup analyses involving different types of cardiac
comorbidity, standardized across multiple institutions, have to be
performed in a bigger future study, taking into account also the
severity of the cardiac disorder type. Such analyses should be cast
against the analyses of cardiac functions and parameters of lung
cancer patients who have never been treated for cardiac patholo-
gies in a cardiology department.
Choosing a suitable measure of RILT is likewise challenging,
[6,32–35]. Dyspnea is a clinical outcome measured qualitatively,
and can be brought about by non-radiotherapy related causes. A
chest X-ray or a CT scan can be used as well, whereby radiation
pneumonitis (1–6 months) and/or ﬁbrosis (1–2 years) could be de-
tected after lung irradiation, both of which cause dyspnea, [36].
However, in many cases radiation pneumonitis is clinically asymp-
tomatic [6]. We therefore chose for dyspnea as a measure for RILT,
since it is clinically the most relevant factor.
One study, [37], evaluated treatment-related cardiac toxicity in
64 breast cancer patients treated with sequential RCHT. None of
the patients had a cardiovascular history or echocardiographic
abnormalities at the start of RT. Left ventricular ejection fraction
(LVEF) was measured at baseline as well as during follow-up.
Twenty-one patients (32.8%) had a short-term decrease in LVEF,
with a median decrease of 10%. These and our ﬁndings suggest that
future research could concentrate on performing echocardiography
before the start of radiotherapy to detect and/or quantify cardiac
pathologies and to test whether asymptomatic heart problems
are likewise associated with RILT in the same fashion as the symp-
tomatic ones we examined. Another study, [38], did not ﬁnd a sta-
tistically signiﬁcant association between LVEF 6 50% and radiation
pneumonitis grade III/IV according to the Common Toxicity Crite-
ria, although the reported odds ratio was 2.15; the overall inci-
dence of radiation pneumonitis was however low: only 3 out of
130 patients (2.3%). Cardiac toxicity blood biomarkers for patients
undergoing R(CH)T could also be considered, such as increases in
troponin and brain natriuretic peptide, [39,40], but such studies
have shown conﬂicting results, [31].
Patient’s smoking status is a potential confounding factor,
which could arguably provide an alternative explanation of our
main ﬁndings. However, current smoking status was not found to
be signiﬁcant in univariate analysis. On the other hand, smoking
status is strongly associated with the presence of cardiac disorders,
but has also been shown to be protective of RILT, [41]. In general it
is the cause of about 15% of all cases of heart failure, [42]. In our
(training) dataset, approximately 22% of the patients with cardiac
comorbidity were current smokers at the start of RT. We tested
therefore for an association between cardiac comorbidity and
smoking status, which we refuted. Similarly, we tested for the che-
motherapy being a confounding factor and found that for the sub-group of patients who received chemotherapy the odds ratio for
developing RILT was virtually the same as for the patients in the
original datasets.
The most commonly used predictive dosimetric parameter for
RILT, the mean lung dose, was not found to be signiﬁcant in our co-
hort. This is to be expected, as prescribed MLD levels had a rela-
tively low mean with a small standard deviation (15.65 Gy ± 4.4)
due to the fact that MLD was used as a dose-limiting factor during
radiotherapy planning. That is why there is arguably insufﬁcient
data to detect a stable upward sloping dose-toxicity response rela-
tionship, such as reported in the QUANTEC study, [3]. This relative
stability of the MLD is actually quite advantageous for the clinical
quality of our prediction models, as it gives the opportunity to ﬁnd
important factors for RILT that are not confounded by largely-vary-
ing levels of MLD.
The role of ACE (angiotensin-converting-enzyme) inhibitors
could also be further investigated. They have been demonstrated
to be both vascular protective and preventive of new acute cardio-
vascular events, and have been proven to play a central role in
afterload reduction in patients with congestive heart failure and
the improvement of cardiac-driven dyspnea complaints, [43,44].
The role of ACE inhibitors for RILT is not clear cut, however. While
a decrease in RILT is reported in preclinical [45] and clinical [46]
studies with ACE inhibitors, other investigations did not reveal a
protective effect at the dose used for the treatment of hypertension
[47].
The role of potential interdependency of cardiac comorbidity,
pulmonary toxicity, and overall survival should be further investi-
gated, as higher incidence of comorbidities in general could inﬂu-
ence both endpoints. In their study, [48], Firat et al. found that
comorbidity inﬂuenced overall survival when the Cumulative Ill-
ness Rating Scale for Geriatrics (CIRS-G) was used to rate the
comorbidity. However, this ﬁnding was not observed with the
Charlson scale.
The existence of cardiac comorbidity at the start of high-dose
RT of lung cancer patients is a major factor for the development
of RILT (deﬁned as maximal dyspnea P2 after radio(chemo)ther-
apy. Moreover, cardiac comorbidity accounted for 43.4% of the inci-
dence of RILT. These results suggest that (1) individualized
treatment should be considered for patients with cardiac comor-
bidity and (2) excluding these patients from dose escalation stud-
ies will potentially allow for better targeting/escalation of the rest
of the patients. It should further be investigated whether asymp-
tomatic patients with cardiac comorbidity develop RILT to the
same extent as the symptomatic ones.Conﬂict of interest
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